Study identifier:D6935C00003
ClinicalTrials.gov identifier:NCT06471257
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized, Double-blind, Multicentre, Event-driven, Parallel group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared with PT007 Administered As Needed in Symptomatic Chinese Adults with Asthma (BAIYUN)
asthma
Phase 3
No
Budesonide/Albuterol metered dose inhaler, MDI, Albuterol sulfate metered dose inhaler, MDI
All
790
Interventional
18 Years - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: BDA MDI BDA MDI 160/180 μg (administered as 2 actuations of BDA MDI 80/90 μg) | Combination Product: Budesonide/Albuterol metered dose inhaler, MDI Combination Product (Drug + Device) Other Name: PT027 |
Active Comparator: AS MDI AS MDI 180 μg (administered as 2 actuations of AS MDI 90 μg) | Combination Product: Albuterol sulfate metered dose inhaler, MDI Combination Product (Drug + Device) Other Name: PT007 |